AstraZeneca’s newly approved cancer pill fails late-stage study, blocking path to bigger market

SERENA-4 was assessing AstraZeneca’s Etcamah as a first-line option for certain patients with advanced breast cancer—a setting that could have meant a $2.9 billion opportunity for the drug.